New clinical and economic outcome data for Verigene blood culture test to be presented at ICAAC conference

Sept. 3, 2014

Nanosphere, Inc., a molecular diagnostics company, has announced that three outcomes studies demonstrating the clinical and economic impact of the Verigene (Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in Washington, DC, on September 5-9, 2014.

Each of the three studies paired Verigene BC-GP for rapid sepsis diagnostic testing with active antimicrobial stewardship programs to assess the impact on antimicrobial optimization and patient outcomes. Settings included two large teaching institutions and a non-teaching community hospital.

The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The System detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus.

Currently, the multiplexed Verigene assays target infections of the bloodstream, respiratory tract, and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance. Read more about the Verigene System.

Read more